Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.44 EUR | -3.75% | -3.56% | -6.87% |
Jun. 04 | Innate Pharma: positive data in mycosis fungoides | CF |
Jun. 04 | Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.87% | 222M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- IPH Stock
- News Innate Pharma
- Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024